With trusted scientific insight brought to every program, Quotient Sciences is a drug development & manufacturing accelerator helping clients bring molecules to cures, fast.

We pioneered the integration of CRO/CDMO services with Translational Pharmaceutics®—a disruptive platform to enable greater efficiency in drug development. This unique approach integrates drug product manufacturing & clinical testing to reduce costs, improves decision making and accelerate development timelines by up to 12 months.

Our comprehensive drug product (CDMO) services span a variety of dosage forms across early and late stage development, covering formulation development, clinical trial, and commercial manufacturing. e specialize in technologies for solubility enhancement, modified release, pediatric products, HPAPIs, and oral peptides. Our clinical pharmacology (CRO) services are focused on early phase, including Phase I studies from first-in-human (FIH), single and multiple ascending dose (SAD / MAD) to regulatory and exploratory clinical studies including human ADME, TQT, DDI, and bioavailability. For all projects, the customer experience is paramount, with expert project managers leading every aspect—from project start-up through to reporting.

With drug product development, manufacturing, and clinical testing facilities located in both the US and the UK, Quotient Sciences has worked with customers as a trusted CRDMO partner for over 35 years. Our approach to program design and delivery saves time in getting new therapies to market, without compromising quality and control of the product, data, and processes along the way.

Our core services include:

• Formulation development
• Clinical trial manufacturing
• Commercial manufacturing;
• Clinical pharmacology
• Data sciences
• Drug development consulting

Early Clinical Development Services:

Dedicated to early clinical development, Quotient Sciences can help accelerate your molecule to your first-in-human and proof of concept milestones. We also offer a range of exploratory and regulatory-driven Phase I clinical pharmacology studies for registration and product labelling purposes.

We are focused on delivering the insight you need by offering end-to-end services to manage every aspect of your early clinical program. Our experience spans more than 30 years with more than 1,300 Phase I studies delivered at our clinical units in Miami and Nottingham.​

• First-in-Human (FIH) to Proof-of-Concept (POC) Clinical Studies

We can help you with solutions that:

• Seamlessly integrate early clinical programs, including SAD/MAD in healthy volunteers and patient cohorts for initial POC, looking at a range of biomarkers. Integrated bioanalysis, PK and data sciences enables rapid turnaround of data and reporting.
• Provide access to special populations and patients for POC assessments.
• Keep you in control of your program. Our programs are led by experienced project management and medical staff, with scientific and regulatory support. We aim to keep your clinical study on-course, while always keeping volunteer and patient safety in mind.

• Phase I Clinical Pharmacology, Regulatory & Labeling Studies

Achieve your molecule’s full potential with our extensive experience in clinical testing. We can help you with clinical solutions that:

• Meet your exploratory, registration and product labeling studies. Our full range of clinical pharmacology studies include DDI, human ADME, BA/BE, and more. These can be run individually or as part of a package to streamline your clinical testing.
• Enable access to healthy volunteers and special populations, such as healthy smokers, healthy elderly, high BMI, or post-menopausal women for your Phase 1 study.